Single-Cell Analysis of the Multiple Myeloma Microenvironment after Gamma-Secretase Inhibition and CAR T-Cell Therapy

Request Access

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.

A. Cowan, M. Pont, Blythe Sather, et al.. (2023). The Lancet. Oncology. Cited 66 times. https://doi.org/10.1016/S1470-2045(23)00246-2
NCPI Dataset Catalog
Feedback & Support
v0.10.0-b29ba7e